trending Market Intelligence /marketintelligence/en/news-insights/trending/yj0oql7tdbtwsmv0qm9o0q2 content esgSubNav
In This List

Acacia Pharma to go public on Euronext Brussels

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Acacia Pharma to go public on Euronext Brussels

Acacia Pharma Ltd is planning to list its stock on the Euronext Brussels stock exchange.

The privately held U.K. company will use the initial global offering to raise funds for Baremsis, which is meant to treat post-surgery nausea and vomiting.

The medicine is under review in the U.S. and is expected to be launched early next year. The company plans to establish a sales force that will help commercialize the drug.

The company is also developing APD403 to treat nausea and vomiting in cancer patients receiving chemotherapy and will also funnel funds toward that effort.

Bank Degroof Petercam NV/SA and RBC Europe Ltd. are acting as joint global coordinators for the global offering.